B. Riley Wealth Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

B. Riley Wealth Advisors’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-5	Closed	–	–	2422
2014 Q4	$0	Buy	+5	New	+$54	﹤0.01%	3805
2014 Q3	–	Sell	-5	Closed	-$87	–	2246
2014 Q2	$87	Buy	+5	New	+$88	﹤0.01%	2448

Other funds holding CASC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

B. Riley Wealth Advisors's CASC Position: Q1 2015 in Review

B. Riley Wealth Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2015, closing a stake of 5 shares.

B. Riley Wealth Advisors first reported a position in CASC in Q2 2014 and held it in 2 quarters. The position peaked at $87 in Q2 2014. 90 funds tracked by Wall St. Rank hold CASC as of Q1 2015.

B. Riley Wealth Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
B. Riley Wealth Advisors sold 5 Cascadian Therapeutics, Inc. shares in Q1 2015.
B. Riley Wealth Advisors first reported a position in Cascadian Therapeutics, Inc. in Q2 2014 and held it in 2 quarters.
B. Riley Wealth Advisors's Cascadian Therapeutics, Inc. position peaked at $87 in Q2 2014.
90 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2015.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2015, filed 14 May 2015.